18 Feb

StopTB/GDF’s Paediatric Drug-Resistant TB (DR-TB) Donation Initiative

The Paediatric Drug-Resistant TB Donation Initiative is led and funded by the Stop TB Partnership’s Global Drug Facility in partnership and with financial support from USAID.

Sentinel_0226_02 StopTB-GDFLogo_CMYK_5cm (1)

Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide

Standard Operating Procedures for Administration of Dispersible Formulations of Second-Line Drugs For Clinical/Nursing Personnel

Drug Sheets for Dispersible Formulations

DR-TB & Me: Caring for a child with drug resistant TB

Standard Operating Procedures for Storage and Administration of Dispersible Formulations of Second-Line for Pharmacy Personnel

Pediatric Formulations of Second-Line Drugs for the Treatment of Drug-Resistant Tuberculosis

Summary Points on Pediatric Formulations of Second-Line Drugs for Tuberculosis

11 Jul

Recommendations for Injectable-Free Regimens in Children with Rifampin-Resistant Tuberculosis

In June 2018, the South African National Department of Health announced that bedaquiline will now be used to replace the injectable agent in routine treatment of rifampin-resistant and multidrug resistant tuberculosis (RR/MDR-TB) in patients over 12 years of age. We congratulate the leadership of the South African National TB program for taking this important step.

We note with some concern that children under the age of 12 years may be precluded from accessing the benefits of an all-oral RR/MDR-TB regimen. As such, we call for policies to support all-oral regimens for patients under 12 years of age in South Africa and globally.  In partnership with the Desmond Tutu Tuberculosis Centre (DTTC) and Treatment Action Group (TAG), Sentinel Project has developed the following recommendations for injectable-free regimens for children under the age of 12 years.
Please download these recommendations here: Recommendations for Injectible-Free Regimens in Children with Rifampacin Resistant TB.